AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
SEROUS CARCINOMA OF THE UTERUS TREATED WITH CISPLATIN, DOXORUBICIN AND ETOPOSIDE
Authors: CHAMBERS JT RUTHERFORD TJ BAKER L KOHORN EI SCHWARTZ PE CARCANGIU ML CHAMBERS SK
Citation: Jt. Chambers et al., SEROUS CARCINOMA OF THE UTERUS TREATED WITH CISPLATIN, DOXORUBICIN AND ETOPOSIDE, International journal of gynecological cancer, 8(3), 1998, pp. 193-196
UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN EPITHELIAL OVARIAN-CANCER - APOOR PROGNOSTIC FACTOR, ASSOCIATED WITH ADVANCED-STAGE
Authors: CHAMBERS SK IVINS CM CARCANGIU ML
Citation: Sk. Chambers et al., UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN EPITHELIAL OVARIAN-CANCER - APOOR PROGNOSTIC FACTOR, ASSOCIATED WITH ADVANCED-STAGE, International journal of gynecological cancer, 8(3), 1998, pp. 242-250
EFFECTIVE TREATMENT OF STAGE-I UTERINE PAPILLARY SEROUS CARCINOMA WITH HIGH-DOSE-RATE VAGINAL APEX RADIATION (IR-192) AND CHEMOTHERAPY
Authors: TURNER BC KNISELY JPS KACINSKI BM HAFFTY BG GUMBS AA ROBERTS KB FRANK AH PESCHEL RE RUTHERFORD TJ EDRAKI B KOHORN EI CHAMBERS SK SCHWARTZ PE WILSON LD
Citation: Bc. Turner et al., EFFECTIVE TREATMENT OF STAGE-I UTERINE PAPILLARY SEROUS CARCINOMA WITH HIGH-DOSE-RATE VAGINAL APEX RADIATION (IR-192) AND CHEMOTHERAPY, International journal of radiation oncology, biology, physics, 40(1), 1998, pp. 77-84
PLASMINOGEN-ACTIVATOR INHIBITOR-1 IS AN INDEPENDENT POOR PROGNOSTIC FACTOR FOR SURVIVAL IN ADVANCED-STAGE EPITHELIAL OVARIAN-CANCER PATIENTS
Authors: CHAMBERS SK IVINS CM CARCANGIU ML
Citation: Sk. Chambers et al., PLASMINOGEN-ACTIVATOR INHIBITOR-1 IS AN INDEPENDENT POOR PROGNOSTIC FACTOR FOR SURVIVAL IN ADVANCED-STAGE EPITHELIAL OVARIAN-CANCER PATIENTS, International journal of cancer, 79(5), 1998, pp. 449-454
CA-125 MAY NOT REFLECT DISEASE STATUS IN PATIENTS WITH UTERINE SEROUSCARCINOMA
Authors: PRICE FV CHAMBERS SK CARCANGIU ML KOHORN EI SCHWARTZ PE CHAMBERS JT
Citation: Fv. Price et al., CA-125 MAY NOT REFLECT DISEASE STATUS IN PATIENTS WITH UTERINE SEROUSCARCINOMA, Cancer, 82(9), 1998, pp. 1720-1725
OVEREXPRESSION OF EPITHELIAL MACROPHAGE-COLONY-STIMULATING FACTOR (CSF-1) AND CSF-1 RECEPTOR - A POOR PROGNOSTIC FACTOR IN EPITHELIAL OVARIAN-CANCER, CONTRASTED WITH A PROTECTIVE EFFECT OF STROMAL CSF-1
Authors: CHAMBERS SK KACINSKI BM IVINS CM CARCANGIU ML
Citation: Sk. Chambers et al., OVEREXPRESSION OF EPITHELIAL MACROPHAGE-COLONY-STIMULATING FACTOR (CSF-1) AND CSF-1 RECEPTOR - A POOR PROGNOSTIC FACTOR IN EPITHELIAL OVARIAN-CANCER, CONTRASTED WITH A PROTECTIVE EFFECT OF STROMAL CSF-1, Clinical cancer research, 3(6), 1997, pp. 999-1007
PHARMACOKINETIC AND PHASE-I TRIAL OF INTRAPERITONEAL CARBOPLATIN AND CYCLOSPORINE IN REFRACTORY OVARIAN-CANCER PATIENTS
Authors: CHAMBERS SK CHAMBERS JT DAVIS CA KOHORN EI SCHWARTZ PE LORBER MI HANDSCHUMACHER RE PIZZORNO G
Citation: Sk. Chambers et al., PHARMACOKINETIC AND PHASE-I TRIAL OF INTRAPERITONEAL CARBOPLATIN AND CYCLOSPORINE IN REFRACTORY OVARIAN-CANCER PATIENTS, Journal of clinical oncology, 15(5), 1997, pp. 1945-1952
GENDER, PRIOR KNOWLEDGE, INTEREST, AND EXPERIENCE IN ELECTRICITY AND CONCEPTUAL CHANGE TEXT MANIPULATIONS IN LEARNING ABOUT DIRECT-CURRENT
Authors: CHAMBERS SK ANDRE T
Citation: Sk. Chambers et T. Andre, GENDER, PRIOR KNOWLEDGE, INTEREST, AND EXPERIENCE IN ELECTRICITY AND CONCEPTUAL CHANGE TEXT MANIPULATIONS IN LEARNING ABOUT DIRECT-CURRENT, Journal of research in science teaching, 34(2), 1997, pp. 107-123
EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-2 IN EPITHELIAL OVARIAN-CANCER - A FAVORABLE PROGNOSTIC FACTOR-RELATED TO THE ACTIONS OF CSF-1
Authors: CHAMBERS SK IVINS CM CARCANGIU ML
Citation: Sk. Chambers et al., EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-2 IN EPITHELIAL OVARIAN-CANCER - A FAVORABLE PROGNOSTIC FACTOR-RELATED TO THE ACTIONS OF CSF-1, International journal of cancer, 74(6), 1997, pp. 571-575
MODULATION OF PLATINUM SENSITIVITY AND RESISTANCE BY CYCLOSPORINE-A IN REFRACTORY OVARIAN AND FALLOPIAN-TUBE CANCER-PATIENTS - A PHASE-II STUDY
Authors: CHAMBERS SK DAVIS CA SCHWARTZ PE KOHORN EI CHAMBERS JT
Citation: Sk. Chambers et al., MODULATION OF PLATINUM SENSITIVITY AND RESISTANCE BY CYCLOSPORINE-A IN REFRACTORY OVARIAN AND FALLOPIAN-TUBE CANCER-PATIENTS - A PHASE-II STUDY, Clinical cancer research, 2(10), 1996, pp. 1693-1697
PHASE-I TRIAL OF INTRAVENOUS CARBOPLATIN AND CYCLOSPORINE-A IN REFRACTORY GYNECOLOGIC CANCER-PATIENTS
Authors: CHAMBERS SK DAVIS CA CHAMBERS JT SCHWARTZ PE LORBER MI HANDSCHUMACHER RE
Citation: Sk. Chambers et al., PHASE-I TRIAL OF INTRAVENOUS CARBOPLATIN AND CYCLOSPORINE-A IN REFRACTORY GYNECOLOGIC CANCER-PATIENTS, Clinical cancer research, 2(10), 1996, pp. 1699-1704
COMBINATION CHEMOTHERAPY WITH ETOPOSIDE, CISPLATIN, AND DOXORUBICIN IN MIXED MULLERIAN TUMORS OF THE ADNEXA
Authors: CASS I RESNIK E CHAMBERS JT CHAMBERS SK CARCANGIU ML KOHORN EI SCHWARTZ PE
Citation: I. Cass et al., COMBINATION CHEMOTHERAPY WITH ETOPOSIDE, CISPLATIN, AND DOXORUBICIN IN MIXED MULLERIAN TUMORS OF THE ADNEXA, Gynecologic oncology, 61(3), 1996, pp. 309-314
RADIATION-THERAPY AS EXCLUSIVE TREATMENT FOR MEDICALLY INOPERABLE PATIENTS WITH STAGE-I AND STAGE-II ENDOMETRIOID CARCINOMA OF THE ENDOMETRIUM
Authors: FISHMAN DA ROBERTS KB CHAMBERS JT KOHORN EI SCHWARTZ PE CHAMBERS SK
Citation: Da. Fishman et al., RADIATION-THERAPY AS EXCLUSIVE TREATMENT FOR MEDICALLY INOPERABLE PATIENTS WITH STAGE-I AND STAGE-II ENDOMETRIOID CARCINOMA OF THE ENDOMETRIUM, Gynecologic oncology, 61(2), 1996, pp. 189-196
UTERINE PAPILLARY SEROUS CARCINOMA TREATED WITH INTRAPERITONEAL CISPLATIN AND INTRAVENOUS DOXORUBICIN AND CYCLOPHOSPHAMIDE
Authors: CHAMBERS JT CHAMBERS SK KOHORN EI CARCANGIU ML SCHWARTZ PE
Citation: Jt. Chambers et al., UTERINE PAPILLARY SEROUS CARCINOMA TREATED WITH INTRAPERITONEAL CISPLATIN AND INTRAVENOUS DOXORUBICIN AND CYCLOPHOSPHAMIDE, Gynecologic oncology, 60(3), 1996, pp. 438-442
PARAMETRIAL INVOLVEMENT, REGARDLESS OF NODAL STATUS - A POOR PROGNOSTIC FACTOR FOR CERVICAL-CANCER
Authors: ZREIK TG CHAMBERS JT CHAMBERS SK
Citation: Tg. Zreik et al., PARAMETRIAL INVOLVEMENT, REGARDLESS OF NODAL STATUS - A POOR PROGNOSTIC FACTOR FOR CERVICAL-CANCER, Obstetrics and gynecology, 87(5), 1996, pp. 741-746
MALIGNANT UTERINE SMOOTH-MUSCLE TUMORS - ROLE OF ETOPOSIDE, CISPLATIN, AND DOXORUBICIN (EPA) CHEMOTHERAPY
Authors: RESNIK E CHAMBERS SK CARCANGIU ML KOHORN EI SCHWARTZ PE CHAMBERS JT
Citation: E. Resnik et al., MALIGNANT UTERINE SMOOTH-MUSCLE TUMORS - ROLE OF ETOPOSIDE, CISPLATIN, AND DOXORUBICIN (EPA) CHEMOTHERAPY, Journal of surgical oncology, 63(3), 1996, pp. 145-147
ARE CONCEPTUAL CHANGE APPROACHES TO LEARNING SCIENCE EFFECTIVE FOR EVERYONE - GENDER, PRIOR SUBJECT-MATTER INTEREST, AND LEARNING ABOUT ELECTRICITY
Authors: CHAMBERS SK ANDRE T
Citation: Sk. Chambers et T. Andre, ARE CONCEPTUAL CHANGE APPROACHES TO LEARNING SCIENCE EFFECTIVE FOR EVERYONE - GENDER, PRIOR SUBJECT-MATTER INTEREST, AND LEARNING ABOUT ELECTRICITY, Contemporary educational psychology, 20(4), 1995, pp. 377-391
A PHASE-II STUDY OF ETOPOSIDE, CISPLATIN, AND DOXORUBICIN CHEMOTHERAPY IN MIXED MULLERIAN TUMORS (MMT) OF THE UTERUS
Authors: RESNIK E CHAMBERS SK CARCANGIU ML KOHORN EI SCHWARTZ PE CHAMBERS JT
Citation: E. Resnik et al., A PHASE-II STUDY OF ETOPOSIDE, CISPLATIN, AND DOXORUBICIN CHEMOTHERAPY IN MIXED MULLERIAN TUMORS (MMT) OF THE UTERUS, Gynecologic oncology, 56(3), 1995, pp. 370-375
EXTRAMAMMARY PAGETS-DISEASE OF THE VULVA
Authors: FISHMAN DA CHAMBERS SK SCHWARTZ PE KOHORN EI CHAMBERS JT
Citation: Da. Fishman et al., EXTRAMAMMARY PAGETS-DISEASE OF THE VULVA, Gynecologic oncology, 56(2), 1995, pp. 266-270
CLINICAL STAGE-I ENDOMETRIAL CARCINOMA - PITFALLS IN PREOPERATIVE ASSESSMENT WITH MR-IMAGING - WORK-IN-PROGRESS
Authors: SCOUTT LM MCCARTHY SM FLYNN SD LANGE RC LONG F SMITH RC CHAMBERS SK KOHORN E SCHWARTZ P CHAMBERS JT
Citation: Lm. Scoutt et al., CLINICAL STAGE-I ENDOMETRIAL CARCINOMA - PITFALLS IN PREOPERATIVE ASSESSMENT WITH MR-IMAGING - WORK-IN-PROGRESS, Radiology, 194(2), 1995, pp. 567-572
MACROPHAGE-COLONY-STIMULATING FACTOR MEDIATES INVASION OF OVARIAN-CANCER CELLS THROUGH UROKINASE
Authors: CHAMBERS SK WANG YX GERTZ RE KACINSKI BM
Citation: Sk. Chambers et al., MACROPHAGE-COLONY-STIMULATING FACTOR MEDIATES INVASION OF OVARIAN-CANCER CELLS THROUGH UROKINASE, Cancer research, 55(7), 1995, pp. 1578-1585
THE SIGNIFICANCE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, ITS INHIBITORS, AND ITS RECEPTOR IN ASCITES OF PATIENTS WITH EPITHELIAL OVARIAN-CANCER
Authors: CHAMBERS SK GERTZ RE IVINS CM KACINSKI BM
Citation: Sk. Chambers et al., THE SIGNIFICANCE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, ITS INHIBITORS, AND ITS RECEPTOR IN ASCITES OF PATIENTS WITH EPITHELIAL OVARIAN-CANCER, Cancer, 75(7), 1995, pp. 1627-1633
MESSENGER-RNA DECAY OF MACROPHAGE-COLONY-STIMULATING FACTOR IN HUMAN OVARIAN CARCINOMAS IN-VITRO
Authors: CHAMBERS SK KACINSKI BM
Citation: Sk. Chambers et Bm. Kacinski, MESSENGER-RNA DECAY OF MACROPHAGE-COLONY-STIMULATING FACTOR IN HUMAN OVARIAN CARCINOMAS IN-VITRO, Journal of the Society for Gynecologic Investigation, 1(4), 1994, pp. 310-316
CHEMOTHERAPY OF RECURRENT ADVANCED CERVICAL-CANCER - RESULTS OF THE YALE-UNIVERSITY PBM PFU PROTOCOL
Authors: CHAMBERS SK LAMB L KOHORN EI SCHWARTZ PE CHAMBERS JT
Citation: Sk. Chambers et al., CHEMOTHERAPY OF RECURRENT ADVANCED CERVICAL-CANCER - RESULTS OF THE YALE-UNIVERSITY PBM PFU PROTOCOL, Gynecologic oncology, 53(2), 1994, pp. 161-169
POSTTRANSCRIPTIONAL REGULATION OF C-FMS PROTOONCOGENE EXPRESSION BY DEXAMETHASONE AND OF CSF-1 IN HUMAN BREAST CARCINOMAS IN-VITRO
Authors: CHAMBERS SK WANG YX GILMOREHEBERT M KACINSKI BM
Citation: Sk. Chambers et al., POSTTRANSCRIPTIONAL REGULATION OF C-FMS PROTOONCOGENE EXPRESSION BY DEXAMETHASONE AND OF CSF-1 IN HUMAN BREAST CARCINOMAS IN-VITRO, Steroids, 59(9), 1994, pp. 514-522
Risultati: 1-25 | 26-30